HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Mineralys Therapeutics (NASDAQ: MLYS) and maintained a price target of $56 for the stock.